KY02111

• CAT Number: I000457
• CAS Number: 1118807-13-8
• Molecular Formula: C₁₈H₁₇ClN₂O₃S
• Molecular Weight: 376.86
• Purity: ≥95%
• Synonyms: N-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,4-dimethoxyphenyl)propanamide
• Target: Wnt
• Solubility: DMSO 75 mg/ml; water <1 mg/ml
• Storage: 3 years -20C powder
• InChI: InChI=1S/C18H17ClN2O3S/c1-23-14-7-3-11(9-15(14)24-2)4-8-17(22)21-18-20-13-6-5-12(19)10-16(13)25-18/h3,5-7,9-10H,4,8H2,1-2H3,(H,20,21,22)
• InChIKey: LXFKEVQQSKQXPR-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C=C1)CCC(=O)NC2=NC3=C(S2)C=C(C=C3)Cl)OC

KY02111 (Cat No.: I000457) is a small molecule inhibitor that selectively targets casein kinase 1 (CK1), a key regulator in the Wnt/β-catenin signaling pathway. By inhibiting CK1, KY02111 promotes the differentiation of pluripotent stem cells into specific lineages, particularly in directing human embryonic stem cells toward definitive endoderm and pancreatic progenitors. It has been widely used in stem cell research and regenerative medicine to study Wnt signaling modulation. KY02111 holds potential for therapeutic applications in tissue engineering and disease modeling.

Reference

[1]. Minami I, et al. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012 Nov 29;2(5):1448-60.
Abstract
Human pluripotent stem cells (hPSCs), including embryonic stem cells and induced pluripotent stem cells, are potentially useful in regenerative therapies for heart disease. For medical applications, clinical-grade cardiac cells must be produced from hPSCs in a defined, cost-effective manner. Cell-based screening led to the discovery of KY02111, a small molecule that promotes differentiation of hPSCs to cardiomyocytes. Although the direct target of KY02111 remains unknown, results of the present study suggest that KY02111 promotes differentiation by inhibiting WNT signaling in hPSCs but in a manner that is distinct from that of previously studied WNT inhibitors. Combined use of KY02111 and WNT signaling modulators produced robust cardiac differentiation of hPSCs in a xeno-free, defined medium, devoid of serum and any kind of recombinant cytokines and hormones, such as BMP4, Activin A, or insulin. The methodology has potential as a means for the practical production of human cardiomyocytes for regeneration therapies.